Clinical Characteristics of CARD14-Associated Papulosquamous Eruption and Evaluation of Therapeutic Efficacy of Secukinumab
The mutation types in <i>CARD14</i>-associated papulosquamous eruption were various. IL-17A inhibitors, such as secukinumab, can be an alternative treatment option for pediatric patients with CAPE.
Authors
- Xinrong Zhao (ORCID: https://orcid.org/0000-0003-2493-9031)
- Zigang Xu (ORCID: https://orcid.org/0000-0001-8645-1854)
- Yunliu Chen (ORCID: https://orcid.org/0000-0003-2259-6442)
- Chaoyang Miao (ORCID: https://orcid.org/0000-0003-3454-9897)
- Xin Xiang (ORCID: https://orcid.org/0000-0003-3510-5649)
- Yuanxiang Liu (ORCID: https://orcid.org/0000-0001-9622-7899)
- Zhaoyang Wang (ORCID: https://orcid.org/0000-0002-4300-6555)
Institutions
- Beijing Children’s Hospital (CN)
Publication Details
- Journal
- Journal of Inflammation Research
- Published
- 2025-05-01
- DOI
- https://doi.org/10.2147/jir.s519554
- Citations
- 2
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 4.01